Session » Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1822

A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia

1:00PM-3:00PM: Abstract Number: 1817

Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample

1:00PM-3:00PM: Abstract Number: 1808

Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout

1:00PM-3:00PM: Abstract Number: 1816

Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study

1:00PM-3:00PM: Abstract Number: 1826

Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1819

Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis

1:00PM-3:00PM: Abstract Number: 1806

Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing

1:00PM-3:00PM: Abstract Number: 1794

Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department

1:00PM-3:00PM: Abstract Number: 1821

Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout

1:00PM-3:00PM: Abstract Number: 1815

Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease

1:00PM-3:00PM: Abstract Number: 1792

Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis

1:00PM-3:00PM: Abstract Number: 1805

Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares

1:00PM-3:00PM: Abstract Number: 1829

Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

1:00PM-3:00PM: Abstract Number: 1824

eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy

1:00PM-3:00PM: Abstract Number: 1799

Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists

1:00PM-3:00PM: Abstract Number: 1797

Factors Driving Opioid Use in United States Veterans with Gout

1:00PM-3:00PM: Abstract Number: 1810

Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study

1:00PM-3:00PM: Abstract Number: 1789

Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital

1:00PM-3:00PM: Abstract Number: 1798

Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

1:00PM-3:00PM: Abstract Number: 1818

Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography

1:00PM-3:00PM: Abstract Number: 1801

High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis

1:00PM-3:00PM: Abstract Number: 1809

Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial

1:00PM-3:00PM: Abstract Number: 1812

Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)

1:00PM-3:00PM: Abstract Number: 1803

Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials

1:00PM-3:00PM: Abstract Number: 1813

Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis

1:00PM-3:00PM: Abstract Number: 1814

Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial

1:00PM-3:00PM: Abstract Number: 1796

Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans

1:00PM-3:00PM: Abstract Number: 1791

Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease

1:00PM-3:00PM: Abstract Number: 1793

Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center

1:00PM-3:00PM: Abstract Number: 1788

Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time

1:00PM-3:00PM: Abstract Number: 1804

Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies

1:00PM-3:00PM: Abstract Number: 1807

Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis

1:00PM-3:00PM: Abstract Number: 1800

Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice

1:00PM-3:00PM: Abstract Number: 1820

Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls

1:00PM-3:00PM: Abstract Number: 1787

The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study

1:00PM-3:00PM: Abstract Number: 1827

The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques

1:00PM-3:00PM: Abstract Number: 1802

The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy

1:00PM-3:00PM: Abstract Number: 1795

Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease

1:00PM-3:00PM: Abstract Number: 1790

Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?

1:00PM-3:00PM: Abstract Number: 1823

Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)

1:00PM-3:00PM: Abstract Number: 1811

Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares

1:00PM-3:00PM: Abstract Number: 1828

Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound

1:00PM-3:00PM: Abstract Number: 1825

Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].